FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2031911743> ?p ?o ?g. }

• W2031911743 endingPage "104" @default.
• W2031911743 startingPage "89" @default.
• W2031911743 abstract "Cardiovascular Drug ReviewsVolume 16, Issue 2 p. 89-104 Free Access PD-156707: A Selective Endothelin-A Receptor Antagonist Andrew C. G. Uprichard, Corresponding Author Andrew C. G. Uprichard Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USAAddress correspondence and reprint requests to Dr. A. C. G. Uprichard, Drug Development, Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48105, USA.Search for more papers by this authorAlan L. Metz, Alan L. Metz Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this authorHussein Hallak, Hussein Hallak Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this authorStephen J. Haleen, Stephen J. Haleen Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this author Andrew C. G. Uprichard, Corresponding Author Andrew C. G. Uprichard Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USAAddress correspondence and reprint requests to Dr. A. C. G. Uprichard, Drug Development, Parke-Davis Pharmaceutical Research Division, Warner Lambert Company, Ann Arbor, MI 48105, USA.Search for more papers by this authorAlan L. Metz, Alan L. Metz Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this authorHussein Hallak, Hussein Hallak Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this authorStephen J. Haleen, Stephen J. Haleen Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI 48105, USASearch for more papers by this author First published: 02 April 2007 https://doi.org/10.1111/j.1527-3466.1998.tb00347.xCitations: 10AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348: 730–732. 2 Baynash AG, Hosoda K, Giaid A, et al. Interaction of endothelin-3 with endothelin-B receptor is essential for development of epidermal melanocytes and enteric neurons. Cell 1994; 79: 1277–1285. 3 Benigni A, Zoja C, Coma D, et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 1993; 44: 440–444. 4 Cody WL, Doherty AM, He JX, et al. Design of a functional antagonist of endothelin. J Med Chem 1992; 35: 3301–3303. 5 Cody WL, Doherty AM, He JX, et al. The rational design of a highly potent combined ETA- and ETB-receptor antagonist. Med Chem Res 1993; 3: 154–162. 6 Davenport AP, O'Reilly G, Molenaar P, et al. Human endothelin receptors characterized using reverse transcriptase-polymerase chain reaction, in situ hybridization and subtype selective ligands BQ-123 and BQ-3020: Evidence for expression of ETB receptors in human vascular smooth muscle. J Cardiovasc Pharmacol (Suppl 8) 1993; 22: S22–25. 7 Davenport AP, Maguire JJ. Endothelin receptors in human coronary artery-reply. Trends Pharmacol Sci 1994; 5: 136–137. 8 Davenport AP, O'Reilly G, Kuc RE. Endothelin ETA and ETB mRNA and receptors expressed by smooth muscle in the human vasculature: Majority of the ETA sub-type. Br J Pharmacol 1995; 114: 1110–1116. 9 Detweiler DK. Spontaneous and induced arterial disease in the dog: Pathology and pathogenesis. Toxicol Pathol 1989; 17: 94–108. 10 Dogterom P, Zbinden G. Cardiotoxicity of vasodilators and positive inotropic/vasodilating drugs in dogs: An overview. Crit Rev Toxicol 1992; 22: 203–241. 11 Doherty AM. Endothelin: A new challenge. J Med Chem 1992; 35: 1493–1508. 12 Doherty AM, Patt WC, Edmunds JJ, et al. Discovery of a novel series of orally active non-peptide endothelin-A (ETA) receptor-selective antagonists. J Med Chem 1995; 38: 1259–1263. 13 Doherty AM, Uprichard ACG. Discovery and development of an endothelin-A receptor selective antagonist PD 156707. In: RT Borchardt, et al., eds. Integration of pharmaceutical discovery and development: Case histories. New York : Plenum Press, 1998 (in press). 14 Ferro JF, Webb DJ. The clinical potential of endothelin receptor antagonists in cardiovascular medicine. Drugs 1996; 51: 12–27. 15 Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. New Engl J Med 1993; 328: 1732–1739. 16 Godfraind T. Endothelin receptors in human coronary artery. Trends Pharmacol Sci 1994; 15: 136. 17 Haleen SJ, Schroeder R, Walker D, et al. CI-1020 (PD 156707) prevents and reverses pulmonary hypertension in hypoxic rats. J Cardiovasc Pharmacol 1998 (in press). 18 Haleen SJ, Keiser JA, Gallagher KP, et al. Effects of chronic endothelin-A-receptor blockade on the progression of heart failure and survival in the cardiomyopathic hamster. Circulation 1998 (in press). 19 Harron JC, O'Rourke D, Gardiner T, Chakravarthy U, Uprichard ACG, Maxwell AP. Effect of an oral endothelin A receptor antagonist in a rat model of diabetic nephropathy. J Am Soc Nephrol 1997; 8: 637A. 20 Hartman HA. Spontaneous extramural coronary arteritis in dogs. Toxicol Pathol 1989; 17: 138–144. 21 Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852–854. 22 Herman EH, Balazs T, Young R, Earl FL, Krop S, Ferrans V. Acute cardiomyopathy induced by the vasodilating antihypertensive agent Minoxidil. Toxicol Appl Pharmacol 1979; 47: 493–503. 23 Hosoda K, Nakao K, Arai H, et al. Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 1991; 287: 23–26. 24 Hosoda K, Hammer RE, Richardson JA, et al. Targeted and natural (Piebald-Lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 1994; 9: 1267–1276. 25 Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl head Sci USA 1989; 86: 2863–2867. 26 Ishikawa K, Fukami T, Nagase T, et al. Cyclic pentapeptide endothelin antagonists with ETA selectivity. Potency and solubility enhancing modifications. J Med Chem 1992; 35: 2139–2142. 27 Joseph EC, Jones HB, Kerns WD. Characterization of coronary arterial lesions in the dog following administration of SK&F 95654, a phophodiesterase-III inhibitor. Toxicol Pathol 1996; 24: 429–435. 28 Reiser JA, Schroeder RL, Hallak H, Uprichard ACG, Doherty AM, Haleen SJ. Pharmacodynamics of PD 156707, a selective endothelin-A (ETA) antagonist, in acute hypoxic pulmonary hypertension. FASEB J 1997; 11: A36. 29 Kurihara Y, Kurihara H, Suzuki H, et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 1994; 368: 703–710. 30 Masuda Y, Sugo T, Kikuchi T, et al. Receptor binding and antagonist properties of a novel endothelin receptor antagonist Tak-044 (cyclo[d-α-aspartyl-3-{(4-phenylpiperazin-1-yl)carbonyl}-l-alanyl-l-a-aspartyl-d-2-{2-thienyl}glycyl-l-leucyl-d-tryptophyl]disodium salt), in human endothelin A and endothelin B receptors. J Pharmacol Exp Ther 1996; 279: 675–685. 31 McClanahan TB, Mertz TE, Ignasiak DP, Junear PL, Gallagher KP. Effects of endothelin-receptor antagonism with PD 156707 on myocardial stunning in swine. J Cardiovasc Pharmacol 1996; 28: 679–686. 32 McConnell PI, Wang W, Gallagher K, Zucker IH. The effects of a specific endothelin-A (ETA) receptor antagonist on the development of chronic heart failure (HF) in the dog. FASEB J 1996; 10: A430. 33 Mertz TE, McClanahan TB, Flynn MA, et al. Endothelin A receptor antagonism by PD 156707 does not reduce infarct size after coronary artery occlusion/reperfusion in pigs. J Pharmacol Exp Ther 1996; 278: 42–49. 34 Mesfin GM, Shawaryn GG, Higgins MJ. Cardiovascular alterations in dogs treated with hydralazine. Toxicol Pathol 1987; 415: 409–416. 35 Metz AL, Dominick MA, Suchanek G, Gough AW. Acute cardiovascular toxicity induced by an adenosine agonist-antihypertensive in beagles. Toxicol Pathol 1991; 19: 98–107. 36 Miller WL, Redfield MM, Burnett JC. Integrated cardiac, renal, and endocrine actions of endothelin. J Clin Invest 1989; 83: 317–320. 37 Mino N, Kobayashi M, Nakajima A, et al. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ischemic acute renal failure. Eur J Pharmacol 1992; 221: 77–83. 38 Omland T, Lie TJ, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as prognostic indicator on 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573–1579. 39 Onley D, Yenari M, Sun GH, Kunis D, Steinberg GK. The endothelin-A antagonist PD 156707 is not neuroprotective in a model of experimental stroke. Soc Neurosci Abstr 1997; 23: 2440. 40 Patel TR, Galbraith SL, McAuley MA, Doherty AM, Graham DI, McCulloch J. Therapeutic potential of endothelin receptor antagonists in experimental stroke. J Cardiovasc Pharmacol 1995; 26: S412–S415. 41 Patel TR. Therapeutic potential of endothelin receptor antagonists in cerebrovascular disease. CNS Drugs 1996; 5: 293–310. 42 Patel TR, Galbraith S, Graham DI, Hallak H, Doherty AM, McCulloch J. Endothelin receptor antagonist increases cerebral perfusion and reduces ischaemic damage in feline focal cerebral ischaemia. J Cereb Blood Flow Metab 1996; 16: 950–958. 43 Peishoff CE, Lago MA, Ohlstein EH, Elliott JD. Endothelin receptor antagonists. Curr Pharmaceutical Design 1995; 1: 425–440. 44 Potter GS, Johnson RJ, Fink GD. Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 1997; 30: 1578–1584. 45 Reynolds EE, Keiser JA, Haleen SJ, et al. Pharmacological characterization of PD 156707, an orally active ETA-receptor antagonist. J Pharmacol Exp Ther 1995a; 273: 1410–1417. 46 Reynolds EE, Hwang O, Flynn MA, et al. Pharmacological differences between rat and human endothelin B receptors. Biochem Biophys Res Commun 1995; 209: 506–512. 47 Ruben Z, Deslex P, Nash G, Redmond N, Poncet M, Dodd D. Spontaneous disseminated panarteritis in laboratory beagle dogs in a toxicity study: A possible genetic predilection. Toxicol Pathol 1989; 17: 145–152. 48 Sakamoto A, Yanagisawa M, Sakurai T, Takuwa Y, Yanagisawa H, Masaki T. Cloning and functional expression of human cDNA for the ETB endothelin receptor. Biochem Biophys Res Commun 1991; 178: 656–663. 49 Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732–735. 50 Sandusky GE, Means JR, Yeager HK. Coronary artery toxicity in beagle dogs given Indolidan, a type III phosphodiesterase inhibitor. Fund Appl Toxicol 1993; 21: 228–235. 51 Schlaeppi B, Roncari G, Zahm P. Vascular toxicity in dogs associated with overdoses of a novel benzodiazepine receptor partial agonist. Arch Toxicol 1991; 65: 73–80. 52 Sobota JT. Review of cardiovascular findings in humans treated with minoxidil. Toxicol Pathol 1989; 17: 193–202. 53 Sogabe K, Nirei H, Shoubo M, et al. Pharmacological profile of FR 139317, a novel, potent endothelin ETA-receptor antagonist. J Pharmacol Exp Ther 1993; 64: 1040–1046. 54 Spinale FG, Walker JD, Mukherjee R, Iannini JP, Keever AT, Gallagher KP. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: Beneficial effects on left ventricular and myocyte function. Circulation 1997; 95: 1918–1929. 55 Takahashi K, Totsune K, Mouri T. Endothelin in chronic renal failure. Nephron 1994; 66: 373–379. 56 Takasago T, McCulloch J. Endothelin-A receptor blockade reduces infarction after focal cerebral ischemia in the rat. Cereb Blood Flow Metab 1997; 17(1): 661. 57 Tonnessen T, Nasee PA, Kirkedoen KA, Offstad J, Ilebekk A, Christenson G. Endothelin is released from the porcine coronary circulation after short-term ischemia. J Cardiovasc Pharmacol (Suppl 8) 1992; 22: S313–S316. 58 Warner TD, Elliott JD, Ohlstein EH. California dreamin' 'about endothelin: Emerging new therapeutics. Trends Pharmacol Sci 1996; 177–181. 59 Yanagisawa M, Hurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411–415. Citing Literature Volume16, Issue2June 1998Pages 89-104 ReferencesRelatedInformation" @default.
• W2031911743 created "2016-06-24" @default.
• W2031911743 creator A5002249531 @default.
• W2031911743 creator A5020981388 @default.
• W2031911743 creator A5035325770 @default.
• W2031911743 creator A5045784005 @default.
• W2031911743 date "1998-06-01" @default.
• W2031911743 modified "2023-10-14" @default.
• W2031911743 title "PD-156707: A Selective Endothelin-A Receptor Antagonist" @default.
• W2031911743 cites W110785718 @default.
• W2031911743 cites W1968412767 @default.
• W2031911743 cites W1970212373 @default.
• W2031911743 cites W1980762198 @default.
• W2031911743 cites W1985354500 @default.
• W2031911743 cites W1987577833 @default.
• W2031911743 cites W1987811756 @default.
• W2031911743 cites W1988884160 @default.
• W2031911743 cites W1989968601 @default.
• W2031911743 cites W1995862377 @default.
• W2031911743 cites W2007747817 @default.
• W2031911743 cites W2009729566 @default.
• W2031911743 cites W2013082229 @default.
• W2031911743 cites W2018139276 @default.
• W2031911743 cites W2022051858 @default.
• W2031911743 cites W2026926934 @default.
• W2031911743 cites W2032027691 @default.
• W2031911743 cites W2032258992 @default.
• W2031911743 cites W2035047456 @default.
• W2031911743 cites W2037552018 @default.
• W2031911743 cites W2038354943 @default.
• W2031911743 cites W2041013270 @default.
• W2031911743 cites W2043727115 @default.
• W2031911743 cites W2044081421 @default.
• W2031911743 cites W2045434816 @default.
• W2031911743 cites W2045877680 @default.
• W2031911743 cites W2059369537 @default.
• W2031911743 cites W2062351505 @default.
• W2031911743 cites W2064734600 @default.
• W2031911743 cites W2071247562 @default.
• W2031911743 cites W2074170762 @default.
• W2031911743 cites W2086895699 @default.
• W2031911743 cites W2090019796 @default.
• W2031911743 cites W2112707074 @default.
• W2031911743 cites W2123529306 @default.
• W2031911743 cites W2144243188 @default.
• W2031911743 cites W2146046550 @default.
• W2031911743 cites W2151869895 @default.
• W2031911743 cites W2159819952 @default.
• W2031911743 cites W2162804111 @default.
• W2031911743 cites W2323478877 @default.
• W2031911743 cites W2331798828 @default.
• W2031911743 cites W2339003767 @default.
• W2031911743 cites W2411579552 @default.
• W2031911743 cites W2461038707 @default.
• W2031911743 doi "https://doi.org/10.1111/j.1527-3466.1998.tb00347.x" @default.
• W2031911743 hasPublicationYear "1998" @default.
• W2031911743 type Work @default.
• W2031911743 sameAs 2031911743 @default.
• W2031911743 citedByCount "10" @default.
• W2031911743 countsByYear W20319117432012 @default.
• W2031911743 crossrefType "journal-article" @default.
• W2031911743 hasAuthorship W2031911743A5002249531 @default.
• W2031911743 hasAuthorship W2031911743A5020981388 @default.
• W2031911743 hasAuthorship W2031911743A5035325770 @default.
• W2031911743 hasAuthorship W2031911743A5045784005 @default.
• W2031911743 hasBestOaLocation W20319117431 @default.
• W2031911743 hasConcept C126322002 @default.
• W2031911743 hasConcept C134018914 @default.
• W2031911743 hasConcept C144980905 @default.
• W2031911743 hasConcept C149601957 @default.
• W2031911743 hasConcept C170493617 @default.
• W2031911743 hasConcept C2776345702 @default.
• W2031911743 hasConcept C2776885963 @default.
• W2031911743 hasConcept C2778122271 @default.
• W2031911743 hasConcept C71924100 @default.
• W2031911743 hasConcept C98274493 @default.
• W2031911743 hasConceptScore W2031911743C126322002 @default.
• W2031911743 hasConceptScore W2031911743C134018914 @default.
• W2031911743 hasConceptScore W2031911743C144980905 @default.
• W2031911743 hasConceptScore W2031911743C149601957 @default.
• W2031911743 hasConceptScore W2031911743C170493617 @default.
• W2031911743 hasConceptScore W2031911743C2776345702 @default.
• W2031911743 hasConceptScore W2031911743C2776885963 @default.
• W2031911743 hasConceptScore W2031911743C2778122271 @default.
• W2031911743 hasConceptScore W2031911743C71924100 @default.
• W2031911743 hasConceptScore W2031911743C98274493 @default.
• W2031911743 hasIssue "2" @default.
• W2031911743 hasLocation W20319117431 @default.
• W2031911743 hasOpenAccess W2031911743 @default.
• W2031911743 hasPrimaryLocation W20319117431 @default.
• W2031911743 hasRelatedWork W1986060795 @default.
• W2031911743 hasRelatedWork W1989283589 @default.
• W2031911743 hasRelatedWork W1998056753 @default.
• W2031911743 hasRelatedWork W2004835726 @default.
• W2031911743 hasRelatedWork W2028774514 @default.
• W2031911743 hasRelatedWork W2071835876 @default.
• W2031911743 hasRelatedWork W2081767905 @default.
• W2031911743 hasRelatedWork W2355879842 @default.

• next